Sarepta Therapeutics

DNA gene therapy gene editing helix CRISPR

Regenxbio starts pivotal study for DMD gene therapy

Regenxbio’s gene therapy improved muscle function for patients with DMD in a phase 1/2 study, with the biotech rolling the trial into a pivotal study.

Gabrielle Masson Nov 18, 2024 2:24pm

Sarepta axes late-phase DMD drug over safety signal, FDA talks

Nov 7, 2024 7:45am

Sarepta's next DMD drug seems to get the job done in phase 2

Jan 29, 2024 10:49am

FDA's Marks overrules staff drug reviewers 'with trepidation'

Jul 27, 2023 3:05pm

Graphic image of the US from space during the night with lights shining across the country

Santhera offloads North American rights for DMD med to Catalyst

Jun 20, 2023 9:53am

clock time delay cancelled month year hour

FDA needs more time for Sarepta's DMD gene therapy

May 24, 2023 8:39am